Overview

Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas

Status:
COMPLETED
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Clinical Study on the Safety and Effectiveness of low-dose chidamide maintenance therapy after allogeneic hematopoietic stem cell transplantation for T-cell acute lymphoblastic leukemia or T-cell lymphomas.
Phase:
PHASE2
Details
Lead Sponsor:
Zhejiang University
Collaborators:
The Affiliated Hospital of Medical College, Ningbo University
The First Affiliated Hospital of Zhengzhou University
Treatments:
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide